3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
86
Phase 3
53
Phase 1
26
Phase 1/2
13
Phase 2/3
3
Phase 4
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Neoplasms
1
Interventions
Letrozole
6
Tamoxifen
4
Cisplatin
4
Anastrozole
4
ribociclib
3
exemestane
3
Vancomycin
3
Specimen Handling
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Human Papillomavirus Recombinant Vaccine nonavalent
3
Dexamethasone
3
Carboplatin
3
Bevacizumab
3
trametinib
2
toripalimab
2
encorafenib
2
dabrafenib
2
binimetinib
2
atezolizumab
2
asciminib
2
Vincristine
2
Sodium Chloride
2
Rituximab
2
Prednisone
2
Papillomavirus Vaccines
2
Methotrexate
2
Medroxyprogesterone Acetate
2
Lenalidomide
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
durvalumab
×
90 days
×
Clear all
NCT06031233
2026-03-30
MINUTE
Isala
Phase 4
Recruiting
776 enrolled